Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells $650,500.00 in Stock

Key Points

  • Director Josef Parvizi sold 25,000 CeriBell shares for $650,500 at an average price of $26.02, reducing his stake by 2.75%; he retained 882,911 shares.
  • CeriBell reported quarterly revenue of $29.34 million, slightly above estimates, but its loss per share of $0.55 was wider than the expected $0.51 loss.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $31.25; recent targets include $29 from Raymond James and $33 from TD Cowen.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Josef Parvizi sold 25,000 shares of the business's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $26.02, for a total value of $650,500.00. Following the sale, the director directly owned 882,911 shares in the company, valued at $22,973,344.22. The trade was a 2.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CeriBell Trading Down 1.7%

Shares of CBLL stock opened at $25.97 on Wednesday. CeriBell, Inc. has a 1 year low of $12.65 and a 1 year high of $28.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.18 and a quick ratio of 7.79. The stock's 50 day simple moving average is $25.59 and its two-hundred day simple moving average is $21.10. The company has a market cap of $1.01 billion, a PE ratio of -13.39 and a beta of 0.86.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). The company had revenue of $29.34 million during the quarter, compared to the consensus estimate of $29.18 million. CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. Research analysts predict that CeriBell, Inc. will post -2.05 earnings per share for the current year.

Institutional Trading of CeriBell




A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new position in shares of CeriBell during the second quarter valued at approximately $53,000. State of Wyoming bought a new position in shares of CeriBell during the first quarter valued at approximately $62,000. Quantbot Technologies LP bought a new position in shares of CeriBell during the second quarter valued at approximately $112,000. Principal Financial Group Inc. raised its holdings in shares of CeriBell by 71.9% in the first quarter. Principal Financial Group Inc. now owns 23,180 shares of the company's stock worth $425,000 after buying an additional 9,696 shares during the period. Finally, Formula Growth Ltd. purchased a new stake in shares of CeriBell in the second quarter worth approximately $603,000.

Wall Street Analysts Forecast Growth

CBLL has been the topic of several recent research reports. BTIG Research restated a "buy" rating on shares of CeriBell in a report on Wednesday, November 4th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. Weiss Ratings raised shares of CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, October 16th. Barclays upgraded shares of CeriBell to a "neutral" rating in a research report on Tuesday, August 18th. Finally, TD Cowen increased their target price on shares of CeriBell from $29.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $31.25.

Read Our Latest Research Report on CeriBell

About CeriBell

(Get Free Report)

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company's Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.

Featured Articles

Insider Buying and Selling by Quarter for CeriBell (NASDAQ:CBLL)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at CeriBell?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for CeriBell and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles